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ABSTRACT
Objectives: To investigate the possible association of vasculogenic mimicry (VM), VE-cadherin and MIG-7 expression with 
clinicopathological features of women with malignant ovarian masses.
Material and methods: VM was studied with the PAS reaction and VE-cadherin was assessed with immunohistochemistry 
in 108 women with malignant ovarian tumors. Additionally, quantitative expression of MIG-7 mRNA was performed in 
52 ovarian cancers with qRT-PCR.
Results: VM was found in 48/108 cases (44%), more often in higher FIGO stage tumors (83% cases; 40 vs. 8; p = 0.01). High 
expression of VE-cadherin was present in 37% of all ovarian masses. Ovarian tumors without VM more often expressed 
low levels of VE-cadherin than tumors where VM was found (37.6% vs.14.6%). No expression or very low expression of 
MIG-7 mRNA was found in all normal ovarian tissues and in 32 cancer samples. Median RQ of MIG-7 mRNA in tumor samples 
was higher than in normal ovarian tissue (RQ = 0.29 vs. RQ = 0.05, respectively; p < 0.005) and higher than in non-malignant 
ovarian masses (0.98 vs. 0.05 respectively; p = 0.03). Expression of MIG-7 mRNA was significantly correlated with VM 
(p = 0.039). In tumors with PAS-positive structures median RQ MIG-7 mRNA was higher than in  tumors with PAS-negative 
findings (1.89 vs. 0.13 respectively). VE-cadherin expression was more frequently found in tumors where MIG-7 mRNA was 
present (p = 0.004). 
Conclusions: Vasculogenic mimicry exists in malignant ovarian tumors and advanced clinical stages of malignancy are 
accompanied by a high incidence of VM formation. MIG-7 mRNA and VE-cadherin expression may serve as additional 
molecular markers of VM in ovarian malignancies.
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INTRODUCTION
Ovarian cancer  is the leading cause of  gynecological 
malignancies related death in women [1]. The most com-
mon and aggressive cancer forms are characterized by 
early extensive tumor invasion and peritoneal metastases 
which is the reason why the majority of women present in 
the advanced stage of the disease. Despite constant sci-
entific progress and initial success of aggressive surgery 
and chemotherapy in most cases treatments failures are 
observed [2]. The main responsible factors are drug resist-
ance and cancer metastasis, and because of this, discovering 
new molecular factors controlling cancer growth and invent-
ing more effective precisely targeted treatments is impera-
tive [3]. The growth and spread of various solid malignant 
tumors is at least partially dependent on the formation of 
sufficient vascular support [4]. So far the most promising 
antiangiogenic strategies in women with ovarian cancer 
include anti-angiogenesis factors like VEGF antibodies and 
angiopoietin antagonists but other molecules targeting can-
cer angiogenesis with the use of different mechanisms have 
been tested, including Cediranib, a potent inhibitor of VEGF 
Tyrosine Kinase Inhibitor. This drug when administered oral-
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ly has already demonstrated potent activity in both phase 
II and phase III studies [5]. 
Microvascular networks can be formed by several dif-
ferent pathways that include the adaptation of the pre-ex-
isting tissue vessels, intususceptive microvascular growth, 
postnatal vasculogenesis, glomeruloid angiogenesis and 
vasculogenic mimicry (VM) [6]. Vasculogenic mimicry (VM) 
is the formation of fluid-conducting channels by highly 
invasive and genetically deregulated tumor cells [7] . VM 
is important for an alternative tumor pathway of blood 
supply and is frequently found in aggressive types of can-
cers. Tumors containing pseudovascular channels display 
higher malignancy potential, rapid proliferation, and high 
incidence of metastases that spread via a vascular system. 
The PAS-positive human uveal melanomas originally identi-
fied by Maniotis et al. demostrated various patterns includ-
ing: linear, parallel linear, cruciform, half-moon, annuliform, 
and lattice forms [7]. Aggressive ovarian cancer cells are 
capable to generate matrix-rich, embryonic- like, patterned 
networks independent of endothelial cells [8]. These tumors 
are also typically characterized by high plasticity and ability 
to express some specific markers of vascular epithelial cells. 
A remarkable example of plasticity is tumor cell vas-
culogenic mimicry, that was first detected in aggressive 
melanomas and later also in ovarian cancers where tumor 
malignant cells expressed endothelial-associated genes 
and formed new vasculogenic-like networks. To highlight 
matrix-associated vascular channels lined with cancer cells 
the periodic acid Schiff reagents staining (PAS) is typically 
used [9]. PAS-positive vascular channels appear to be an im-
portant alternative pathway of blood supply to the tumors 
that sustains their growth and supports metastasis forma-
tion. The presence of VM is in turn frequently associated with 
a high tumor grade, short survival, invasion and metastasis 
formation [9, 10].
Vascular endothelial cadherin (VE-cadherin) is an ad-
hesive protein and a component of endothelial cell-to-cell 
junctions that plays a key role in the maintenance of vascular 
morphology and stability [11]. Endothelial cells (ECs) express 
various members of the cadherin superfamily, in particular 
vascular endothelial VE-cadherin, which is the main ad-
hesion receptor of endothelial adherent junctions. High 
expression of VE-cadherin by aggressive melanoma tumor 
cells results in their ability to mimic endothelial cells and 
form embryonic-like, patterned, vasculogenic networks [12]. 
VE-cadherin may be detected in highly aggressive malignant 
tumors but not in less-aggressive ones. More recently, ty-
rosine phosphorylation of VE-cadherin has been implicated 
in the disruption of endothelial cell adherent junctions and 
in the diapedesis of metastatic cancer cells [13]. Aberrant 
extra-vascular expression of VE-cadherin has been observed 
in certain cancer types associated with VM [14]. 
Discovery and targeting of tumor cell-specific gene ex-
pressions could lead to more effective cancer managements 
with a reduced amount of toxic side effects. First described 
by Crouch et al. in 2004, who studied MIG-7 protein with 
an antibody to its first nine amino acids and demonstrated 
reproducible and significant inhibition of endometrial car-
cinoma cell invasion in vitro [15]. MIG-7 protein has been 
proposed as one of the essential factors that facilitate tumor 
cell dissemination by aggregate invasion and by promot-
ing the process of vasculogenic mimicry [15]. Expression 
of MIG-7 mRNA can be found at early stage of pregnancy 
during trophoblast development. Except from this site it 
is specific to malignant tumor cells and is not found in 
normal adult cells. Induction of MIG-7 mRNA expression 
is dependent on multiple factors, that include cytokines 
like epidermal growth factor (EGF) and hepatocyte growth 
factor (HGF). It has been suggested that MIG-7 could serve 
as promising marker for circulating cancer cells detection 
and metastasis [16]. MIG-7 protein induces invasion and 
vessel-like structure formation by cancer cells in three di-
mensional (3D) cultures in vitro and the knockdown of 
MIG-7 gene in cancer cells line causes their reduced inva-
sion in 3D cultures. The gene activation promotes lung 
cancer metastases formation by activating the cyclooxy-
genase-2 (COX-2)–prostaglandin E2 (PGE2) signaling cas-
cade [17]. Immunohistochemical (IHC) studies performed 
with MIG-7 antibodies revealed expression of this marker 
in circulating tumor cells, proposing its potential as an early 
marker for metastatic carcinomas [18, 19]. The use of pep-
tides specific to MIG-7 treatment has induced increased 
monocyte expression of tumor necrosis factor (TNF) and 
killing of breast carcinoma cells in vitro [20]. Another hypo- 
thesis is that MIG-7 stimulates vascular mimicry prior to 
tumor angiogenesis, thus contributing to early growth and 
metastasis of ovarian cancer [21]. The aim of the present 
study was to investigate the possible association of vascu-
logenic mimicry, VE-cadherin and MIG-7 mRNA expression 
with selected clinicopathological features of women with 
malignant ovarian masses.
MATERIAL AND METHODS
The studied group included 108 women with ovarian tu-
mors who were operated between years 2009–2011 in the 
Ist Department of Gynecologic Oncology and Gynecology 
of the Medical University of Lublin. All participants were 
informed of the nature of the study and gave their informed 
consent. The average age of patients was 52.3 years (range: 
18 to 86 years). Among them there were 47 premenopau-
sal (44%) and 61 postmenopausal women (56%). Exam-
ined group included 6 cases of benign ovarian masses, 
9 borderline ovarian tumors and 93 malignant ovarian can-
cers. Malignant tumors included 17 metastatic tumors to 
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the ovary and 5 non-epithelial tumors: 3 dysgerminomas 
and 2 granulosa cell tumors. All specimens were examined 
by an experienced pathologist to confirm the diagnosis of 
ovarian malignancy. The proportion of malignant cells in 
selected tumor samples used in this study was always more 
than 50%. The histological type and grade of the tumors 
were classified according to the criteria of the World Health 
Organization (WHO). The clinical stage of each cancer was 
established according to International Federation of Gyne-
cology and Obstetrics (FIGO) criteria.
Immunohistochemical studies
Immunohistochemical staining for PAS and VE cadherin 
was performed in all overian masses. Four-micrometer sec-
tions from formalin-fixed, paraffin-embedded tissue were 
mounted on silanized slides (DAKO Cytomation, Denmark). 
The slides were air-dried and the tissue was deparaffinized 
and rehydrated. For PAS staining, the sections were incu-
bated with periodic acid for 5 min, rinsed with distilled water 
and then incubated with Schiff reagent for 15 min (PAS stain-
ing kit, Sigma, USA), next they were dehydrated, mounted 
and cover slipped. PAS-positive channels with red blood 
cells, as wells as walls composed of tumor cells, were verified 
by hematoxylin-eosin staining (HE staining) and assessed 
and 100× and 200× magnifications (Fig. 1). For the purpose 
of this study all our malignant tumor cases were divided into 
two groups: VM-positive and VM-negative groups.
VE-cadherin expression assessment was performed with 
VE-cadherin (H-72) rabbit polyclonal antibody (Santa Cruz 
Biotechnology, USA). Following deparafinization, rehydrata-
tion and antigen retrieval with the Target Retrieval Solution 
at pH = 6.0 (Dako Cytomation,Denmark), three cycles of 
heating in a microwave oven (each for 5 mins, at 750 W) were 
performed. Tissue sections were incubated with the primary 
antibody for 1 hour in room temperature (dilution: 1:200). 
The slides were incubated with the secondary antibody 
conjugated with streptavidin-biotin-peroxidase complex 
(rabbit/mouse EnVision kit; DAKO Cytomation) and color 
reaction was developed using DAB (3’-3-diaminobenzidine 
tetrahydrochloride, DAKO) according to the manufacturer’s 
protocol. The sections were counterstained with Mayer’s 
hematoxylin. For each case, negative control was applied 
by replacing the antibody with PBS or nonimmune serum.
VE-cadherin expression was assessed semi-quantitative-
ly and both the intensity and percentage of positive cells 
were measured (Fig. 2). As a rule at least 10 microscopic fields 
in one representative tumor section were observed under 
400× magnification. The VE-cadherin intensity of staining 
was graded 0 for absent immunoreactivity, 1 for weak, 
2 for moderate, and 3 for intense positivity. The number of 
Figure 1. Example of PAS-positive structures in ovarian cancer tissues 
(colored in pink). Arrows indicate pseudovascular channels where 
erythrocytes can be found 100× (A). Channel walls surrounded by 
the cancer cells but not endotheliocytes (cell nuclei are circular rather 
than flattened) 200× (B)
Figure 2. An example of VE-cadherin expression in ovarian cancer 
tissue 100× (A). Brown color is apparent in the cytoplasm of tumor 
cells but not in the stromal cells. Selected area in the box on the lower 
picture 400× (B). Arrows indicate pseudovascular channels in which 
some red blood cells can be seen
A
B
A
B
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positive cells was visually evaluated and cell expression was 
stratified as follows: negative; for < 10% positive cells (weak 
or absent reaction), low; for 10–30% positive cells (weak or 
moderate); medium for 31–65% positive cells (moderate or 
strong reaction) and high for > 65% positive cells (strong 
reaction). 
Quantitative real-time -PCR (qRT-PCR)  
for MIG-7 mRNA
Quantitative expression of MIG-7 mRNA was performed 
in 52 ovarian tumors tissue that were collected from consent-
ing patients immediately after tumor removal. The 3–4 mm 
representative tumor samples were snap-frozen in liquid 
nitrogen and stored in –80o C until processing. Ten nonma-
lignant tissue samples were taken from ovaries of women 
who had bilateral oophorectomies for suspected malignancy, 
but were found to have benign histology. The samples were 
collected from apparently normal contralateral ovaries and 
were used as a reference group for qRT-PCR analysis. Total RNA 
was extracted from the ovarian tissues using Trizol Reagent 
(Life Technologies; 1mL/35–45 mg of tissue) according to the 
manufacturer’s protocol. Reverse transcription of total RNA 
was performed with the use of the High Capacity cDNA Re-
verse Transcription Kit (Applied Biosystems) according to the 
supplier’s instructions. Each target was amplified in triplicate 
with a MIG-7— specific primer probe set as described by Petty 
et al. [20] and designed by “Primer 3” v. 0.2 software. The fol-
lowing primer sequences were used in this part of the study: 
forward, 5’-CACCTGCCTCTGGTCGTTAGG-3’; reverse 5’-TACTG-
GATTCCTCTAGCTTTGGTGTT-3’; probe 5’-AAACTCTCAGT-
GATCTCT-3’. For endogenous control a GAPDH primer probe 
set was used (TaqMan® Gene Expression Assay, Hs00182176; 
Applied Biosystems, USA). The expression of GAPDH was 
used for normalization of Real-Time reaction. Real Time PCR 
was performed with the use of 7900HT Fast Real-Time PCR 
System (Applied Biosystems, USA) at 50°C for 2 min and at 
95°C for 10 min, followed by 40 cycles at 95°C for 15 s and at 
60°C for 1 min.  The MIG-7 mRNA relative quantity (RQ) was 
calculated using comparative CT Method (ΔΔ CT Method) 
(ABI User Bulletin no. 2). ΔCT values were generated from 
the housekeeping gene multiplexed in each reaction as the 
endogenous control. The ΔΔCT values were generated by 
comparing the reference gene (GAPDH) to the tested gene 
(MIG-7) in all samples. 
Statistical analysis
Statistical analysis was performed with the use of Sta-
tistica v.6.0 software (Statsoft, Poland). The correlation be-
tween selected clinical and pathological features and the 
expression of VE-cadherin, MIG-7 mRNA, PAS+ structures 
in tumor specimens was analyzed using Pearson’s χ2 test 
or nonparametrical U Mann Whitney and Kruskall-Wallis 
ANOVA tests, where appropriate. The criterion of statistical 
significance applied in all calculations was p < 0.05.
Table 1. Immunohistochemical staining and qRT-PCR results compared with tumor type, FIGO stage and histological grading of studied tumors 
IHC analysis
(PAS staining and VE-cadherin expression)
n = 108
Real time-qPCR
MIG-7mRNA expression
n = 52
Histological grade
G1 26 (24%) 5 (9.6%)
G2 37 (34.3%) 18 (34.6%)
G3 45 (41.7%) 29 (55.7%)
FIGO stage
I 25 (23.1%) 7 (13.4%)
II 6 (5.5%) 1 (1.9%)
III 72 (69.4%) 39 (75%);
IV 5 (4.6%) 2 (3.8%)
Histological subtype
Serous 29 (26.8%) 16 (30%)
Mucinous 9 (8.3%) 3 (5.7%)
Endometroid 21 (19.4%) 16 (30.7%)
Undifferentiated 26 (24%) 10 (19.2%)
Metastatic 17 (15.7%) 6 (11.5%)
germinal* 5 (4.6%) 1 (1.9%)
*three dysgerminomas and  two granulosa cell tumors
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RESULTS
Median age of all studied women was 52.3 years (range: 
18–86 years). The selected clinical and pathologic variables 
of these patients are listed in Table 1. Based on FIGO grade 
and stage, patients were divided into two groups, low stage 
(FIGO stage I and II; n = 31; grade 1 or 2; n = 63) and high 
stage (FIGO stage III or IV, n = 77; grade 3, n = 45). All of 
the forms described by Maniotis et al. [7] were found in 
our group and most of them was parallel, linear, cruciform, 
half-moon and back to back-loop patterns. Besides, red 
blood cells were also found in the pseudovascular channels 
(Fig. 1). There were no PAS-positive structures in both normal 
ovarian tissues and in benign tumors as well as in borderline 
tumors. Vasculogenic mimicry, as confirmed by PAS staining 
was found in 48/108 cases (44%), most commonly in serous 
and endometrioid ovarian cancer subtypes (Table 2). Half 
of metastatic tumors and almost half of the ovarian cancers 
demonstrated PAS-positive structures. In the case of ovar-
ian serous tumors, nearly half (13 of 29; 45%) were charac-
terized by the presence of pseudovascular PAS positive VM 
channels. For endometriod type of cancer, a much as 76% 
(16 of 21 cases) had PAS-positive structures present. In the 
case of clear cell type, no cases of vasculogenic mimicry as 
stained by PAS reaction were found (0 of 4). The differences 
between these groups were statistically significant (p = 0.02). 
VM occurred more often in high FIGO stage tumors (III and 
IV) (83% cases; 40 vs. 8), than in women with low FIGO stage 
cancers (p = 0.01). Age and menopausal status were not 
significantly correlated with the presence of vasculogenic 
mimicry in studied ovarian malignant tumors tissues.
High expression of VE-cadherin (staining intensity 
2 or 3 in over 65% of tumor cells) was present in 37% of all 
cases. Figure 2 shows representative staining patterns for 
VE-cadherin. Low or no expression of VE-cadherin (intensity 
1 or 2 in 40% tumor cells) was found in 27% of tumors (Ta-
ble 3). There was no correlation with histological type of ma-
lignant tumor, FIGO stage or grade (Table 4). The expression 
of VE-cadherin was substantially associated with the pres-
ence of pseudovascular channels (p = 0.002). Ovarian tumors 
without VM more often expressed low levels of VE-cadherin 
than tumors where VM was found (37.6% vs.14.6%). 
Quantitative RT-PCR analysis of total RNA detected 
MIG-7 mRNA expression in 48% (n = 20) of tumor tissues. Me-
dian relative quantity of MIG-7 mRNA in tumor tissue was 
RQ = 0.29 (range 0.04–3.11) (Table 5). In all controls (normal 
ovarian tissue samples) and in 32 cancer samples no ex-
pression or very low expression of MIG-7 mRNA was found 
(RQ = 0.05 range 0.01–0.19). In EOC samples median RQ of 
MIG-7 MRNA was significantly higher than in non-EOC tis-
sue probes (where RQ = 0.98 vs. 0,05 respectively; p = 0.03) 
(Table 6). No correlation of RQ MIG-7 mRNA expression with 
FIGO stage or tumor histological grade was found. Inter-
estingly, high expression of MIG-7 mRNA was frequently 
found in tumors with VM (RQ = 1.89 range 0.05–17.3) and 
in cases without VM median RQ was significantly lower 
(RQ = 0.13 range 0.03–1.57) and the differences between 
Table 2. Association of selected clinicopathological variables with tumor vasculogenic mimicry 
Vasculogenic mimicry
PAS-negative 
n = 60 (56%)
PAS-positive 
n = 48 (44%) p (Chi
2 test)
Histological grading
Low grade
(G1 or G2) 
n = 63
39 (61.9%) 24 (38.1%)
0.08
High grade 
(G3) 
n = 45
21 (46.6%) 24 (53.3%)
FIGO stage
Low (I or II) 
n = 31 23 (74.1%) 8 (25.8%)
0.01
High
(III or IV) n = 77 37 (48.1%) 40 (51.9%)
Histologic subtype
EOC 
n = 59
(serous or mucinous or endometrioides) 
28 (47.4%) 31 (52.5%)
0.06
Non EOC
n = 49
(undifferentiated or metastatic or germinal)
32 (65.3%) 17 (34,69%)
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these groups were statistically significant (p = 0.039). Also, 
a significant relationship between VE-cadherin expres-
sion and MIG-7mRNA presence (p = 0.002) was found. 
In 12 malignant tumor samples where strong VE-cadherin 
staining signal was found median RQ of MIG-7mRNA was 
higher  than in subgroup with medium or low expression of 
VE-cadherin ( where RQ = 44.3 vs. RQ = 1.04; and RQ = 0.05 
for high medium and low VE-cadherin expression, respec-
tively) (Table 6). This correlation was statistically significant 
(p = 0.004).
DISCUSSION
Development of the most appropriate combination of 
anticancer and antivascular therapy in a given ovarian ma-
lignant tumor is a new and extremely important challenge. 
Since its discovery in 1999, vasculogenic mimicry has been 
recognized as alternative blood and nutrient supply network 
that is induced in several types of highly malignant tumor 
types including ovarian high grade cancers. Therefore, this 
study was undertaken to evaluate and correlate VM phe-
nomenon with VE-cadherin and MIG-7 gene expression, 
both of which may play an important role in malignant 
ovarian tumors adequate blood supply that is independent 
from VEGF-driven angiogenesis. Various vasculogenic sign-
aling pathways that are normally restricted become active in 
highly aggressive cancers. Despite many published studies 
to date and significant new insights that they have brought 
to the ovarian cancer angiogenesis the precise mechanisms 
controlling the multipotent vasculogenic mimicry pheno-
type of ovarian cancer are still largely unknown. 
Taking into account histological and clinical character-
istics, we have found that vascular mimicry was present 
primarily in a subset of ovarian malignant tumors that most 
Table 3. Association of malignant ovarian tumors FIGO stage and histological grade with VE-cadherin expression in tumor tissue
VE-cadherin expression
Low 
n = 29 (26.8%)
Medium
n = 39 (36.2%)
High
n = 40 (37%) p (Chi
2 test)
Histological grading
Low grade
(G1 or G2) 
n = 63
17 (26.9%) 23 (36.5%) 23 (36.5%)
0.9
High grade (G3)
 n = 45 12 (26.6%) 16 (35.5%) 17 (37.7%)
FIGO stage
Low (I or II) 
n = 31 8 (25.8%) 11 (35.5%) 12 (38.7%) 0.9
High (III or IV) n = 77 21 (27.3%) 28 (36.3%) 28 (36.3%)
Histologic subtype
EOC
 n = 59
(serous or mucinous or endometrioid) 
12 (20.3%) 23 (38.9%) 24 (40.6%)
0.2
Other
 n = 49
(undifferentiated or metastatic or germinal)
17 (34.6%) 16 (32.6%) 16 (32.6%)
Table 4. Association of VE-cadherin expression with tumor vasculogenic mimicry
VE-cadherin expression Low n = 29
Medium 
n = 39
High 
n = 40 p (Chi
2 test)
Vasculogenic mimicry, n = 108
PAS–(n = 60) 22 (36.7%) 24 (40%) 14 (23.3%)
0.002
PAS+(n = 48) 7 (14.6%) 15 (31.2%) 26 (54.2%)
Table 5. Relative Quantity (RQ) of MIG-7 mRNA assessed by real-time 
qPCR in ovarian tumors and in the control group
RQ-MIG-7 mRNA expression
Median Range Min-max
Control (normal ovarian tissue) 
(n = 10)
0.05 0.01–0.19 0.001–0.27
Tumor tissue  
(n = 52) 
0.29 0.04–3.11 0.001–4711
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often were also highly aggressive. Pseudovascular channels 
were detected in 44% of malignant tumors cases, most 
commonly in serous and endometrioid ovarian cancer sub-
types. Patterned matrix VM was distinct from angiogenic 
vessels on light microscopy because endothelial cell lined 
vessels do not form back-to-back loops in 2-dimensional 
histologic sections. With increasing clinical stage of studied 
tumors, the proportion of VM tumors increased gradually 
showing significant correlation with the presence of VM. We 
hypothesize that in more aggressive ovarian tumors, cancer 
cells initiate VM signaling cascade and proliferate more 
rapidly. The plasticity of these cancer cells is usually higher 
than in slow growing tumors and because of this feature, the 
process of their differentiation is more immature [4, 10]. The 
alternative network of blood supply to the tumor is provided 
even though the rapid cancer growth may not be precisely 
synchronized with tumor angiogenesis. Some tumors cells 
may form abnormal vessel-like vascular channels by excre-
tion of extracellular matrix which helps to form blood cells 
transporting system [9, 20].
Identification of specific genes that are expressed in 
a cancer cell and which are capable of VM formation may be 
further used to find specific molecular markers that can be 
used clinically in the detection and disease progression as-
sessment. Since VM activity is associated with the expression 
of VE-cadherin, together with the Mig-7 gene activation 
may initiate aggressive tumor behavior [21]. Hendrix et al. 
studied in vitro a mouse VM model and have found that if 
VE-cadherin expression was blocked, the formation of new 
pseudovascular channels was not further observed [22]. Our 
Table 6. Association of selected clinical and pathological variables with RQ of MIG-7 mRNA, VE-cadherin expression and vasculogenic mimicry 
in ovarian cancer tissue
MIG-7 mRNA expression (RQ)
Median Range Min–max p –valueU Mann-Whitney test
Histological grading
Well differentiated (G1 or G2) 
n = 23 0.13 0.02–6.76 0.002–4711 Z = –0.45; p = 0.65 
Low differentiated (G3) n = 29 0.98 0.05–0.98 0.001–202
FIGO stage
Low (FIGO I\II) 
n = 11 0.57 0.08–2.91 0.02–385
Z = 0.7; p = 0.48
High (FIGO III\IV)
n = 41 0.17 0.03–3.24 0.001–4711
Histologic subtype
EOC
n = 35
(serous or mucinous or 
endometrioides) 
0.98 0.06–7.38 0.009–4711
Z = 2.1; p = 0.03
Non EOC
n = 17
(undifferentiated or 
metastatic or germinal)
0.05 0.01–1.89 0.001–312
Table 7. Association of MIG-7 mRNA expression (RQ) with vasculogenic mimicry and VE-cadherin expression in ovarian cancer tissue
MIG-7 mRNA (RQ) Median Range Min–max
p-value
(U Mann-Whitney; 
Kruskal-Wallis ANOVA tests)
Vasculogenic mimicry
PAS– (n = 25) 0.13 0.03–1.57 0.001–444
Z = –2.1; 0.039
PAS+ (n = 27) 1.89 0.05–17.3 0.009–4711
VE-cadherin expression
Low (n = 16) 0.05 0.01–0,15 0.001–2.9
H = 10.8; p = 0.004Medium (n = 24) 1.04 0.08–3.11 0.001–444
High (n = 12) 44.3 0.14–257 0.009–4711
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study provides another evidence in support of the hypoth-
esis that expression of VE-cadherin by ovarian cancer cells 
results in their facility to mimic endothelial cells and form 
embryonic-like, patterned vasculogenic networks. In a study 
by Alvero et al. the expression of VE-cadherin was correlated 
with the occurrence of tumor pseudovascular channels [23]. 
They have also found that ovarian cancer cells have the 
capacity to gain an endothelial phenotype and could form 
vessel-like structures in vitro. Authors showed that CD44+/ 
/VE-cadherin−/CD34− Type I EOC cells can differentiate into 
a CD44+/VE-cadherin+/CD34+ phenotype when cultured 
in high-density Matrigel and mimic the behavior of normal 
endothelial cells. This process was complemented by the 
achievement of endothelial marker CD34 and VE-cadher-
in [23]. Wang et al. have found that treatment with VEGF-A in-
crease expression of VE-cadherin in ovarian cancer cells in 
vitro and stimulates vasculogenic mimicry trough stimula-
tion signaling cascade of EphA2 and MMP2 and MMP9 [24]. 
To our knowledge, this is the first report on the expres-
sion of MIG-7 mRNA in ovarian cancer tissues assessed with 
the use of  quantitative real-time PCR. Our results indicate 
that high MIG-7 mRNA expression was detected only in 
a subset of EOC cells but not in cells from normal ovar-
ian tissue samples and not in benign tumor samples. PAS 
staining revealed that in these tumors pseudovascular 
structures were also present. Moreover, we have found 
a significant relationship between high expression of 
MIG-7 mRNA and VE-cadherin. Taken together, these ob-
servations suggest that high expressions of MIG-7 in tumor 
tissues concurrent with high expression of VE-cadherin 
may have a synergistic effect that promotes VM formation. 
Similar results were reported by Petty et al. [17] when these 
investigators analyzed MIG-7 expression in breast cancer. 
They have demonstrated the specificity of MIG-7 expres-
sion to breast cancer tissue as MIG-7 was not detected in 
normal breast tissues nor it was found in blood from nor-
mal subjects. In this study immunohistochemical analyses 
with specific MIG-7 protein antibody showed that staining 
reaction was present in 53% of total breast cancer tissues. It 
is possible that this specificity of MIG-7 expression may be 
activated by multiple tumor microenvironment factors. To 
date, MIG-7 protein was found to be localized on normal 
embryonic cytotrophoblast cells and on cancer cells as 
well as within the lumen of  vessel-like structures. Im-
munohistochemistry demonstrated that MIG-7 protein 
co-localizes with endothelial marker factor VIII, VE-cadherin 
and laminin 5 γ2 domain fragment III [17]. 
More recently, Liao and Gao have studied the immuno-
histochemical expressions of MIG-7-7 and MMP-2 related to 
VM in gastric cancer patients [25]. Vasculogenic mimicry was 
found in 32% of samples and its presence was significantly 
correlated with the tumor grade and lymph nodes metasta-
ses. Expression of MIG-7 was found in 95% of gastric cancer 
cases and was also associated with lymph node metasta-
sis. The expression rates of MIG-7 and MMP-2 were higher in 
the VM-positive group than in the VM-negative group. In this 
study detection of vasculogenic mimicry in tumor samples 
was closely associated with the invasion, metastasis and 
poor prognosis of gastric cancer patients [25].
Currently, anti-VM therapies were proposed by several 
groups of investigators. Most of them aimed to remodel 
the extracellular matrix and tumor microenvironment or 
to block biochemical and molecular signaling pathways 
of VM or to inhibit tumor cell plasticity [26]. With the chal-
lenge of finding new drugs which could inhibit VM, the 
soybeans isoflavone called genistein was proposed. This 
molecule was found to be able to inhibit VM formation of 
uveal melanoma through down-regulation of VE-cadherin in 
vitro [27, 28]. In another study Itzhaki et al. tested the ability 
of nicotinamide to inhibit VM activity in melanoma cells [29]. 
They have found that nicotinamide acted as an epigenetic 
gene regulator and downregulated VE-cadherin expression. 
VE-cadherin was downregulated significantly on both RNA 
and protein levels. Clinical use of novel, targeted therapies 
including angiogenesis inhibitors has revealed new features 
of malignant ovarian tumors and important cancer molecu-
lar pathways checkpoints like MIG-7 activation that could 
be blocked with monoclonal antibodies [30]. 
Several lines of evidence indicate that ovarian cancer 
is a “moving target” and various treatment regimens may 
change its signaling features as well as metabolic character-
istics [3, 4]. Phenotype-switching and plasticity comparable 
to that of embryonic cells is the main reason of complex-
ity of the metastatic phenotype and should be taken into 
consideration when designing new therapies. Moreover, 
the significant heterogeneity within the cancer masses may 
enable escape from conventional therapy and in such cases 
new concurrent and targeted treatment regimens might 
lead to improved tumor responses and cures. Examples 
of other promising new approaches against ovarian can-
cer include targeting aberrant OC signaling such as the 
PI3K/Akt/mTOR network, the epidermal growth factor re-
ceptor, the tyrosine kinase and the folate receptor alpha [5].
Targeting only endothelial cells has no effect on tumor cells 
that are involved in VM network formation. Therefore, there 
is a strong clinical need to develop new ways of targeted 
antivascular modalities which would be based not only 
on cancer stage but also on a type of its vascularization 
[31, 32]. Moreover, specific inhibitors to these molecular 
mechanisms that control specific microvascular network 
need to be developed. The in-depth knowledge on the 
specific VE-cadherin specific signaling pathways and  the 
association with the stem cell-like phenotype may be a key 
component of VM regulation [33].
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CONCLUSIONS
1. Vasculogenic mimicry exists in malignant ovarian tu-
mors and clinical advanced stages of malignancy are 
accompanied by a high incidence of VM formation. 
2. MIG-7 mRNA expression and VE-cadherin assessment 
may serve as additional molecular markers of VM in 
ovarian malignancies.
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